CSL Behring
CSL Behring’s angioedema treatments receives NICE recommendation
September 26, 2025Regulatory Affairs, Research and Development Andembry, CSL Behring, hereditary angioedema
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Behring’s ANDEMBRY (garadacimab) for …
CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany
June 26, 2025Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access
CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …
First UK patient treated with CSL Behring’s gene therapy for Haemophilia B
June 20, 2025Research and Development CSL Behring, Haematology, NHS England, cell therapy, gene therapy, haemophilia B, prophylactic infusions
CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking …
FDA approves CSL Behring’s new haemophilia B treatment
March 7, 2016Research and Development, Sales and Marketing CSL Behring, haemophilia
The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …
CSL Behring launches new dosing app
June 27, 2012Medical Communications Beriplex P/N, CSL Behring, app, digital
Biotherapy firm CSL Behring UK has launched an app for doctors to aid the management of its anaesthetic treatment Beriplex …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
